World’s First AV1 Decoder Silicon IP with Support for 12-bit Pixel Size and 4:4:4 Chroma Sub-Sampling Released by Allegro DVT
16.6.2022 16:30:00 EEST | Business Wire | Press release
Allegro DVT, the leading provider of video processing silicon IPs and video compliance streams, has announced that its D310 AV1 Decoder silicon IP now supports 12-bit sample size and 4:4:4 chroma sub-sampling. Emerging applications such as cloud-gaming, automotive and screen mirroring will directedly benefit from these new features to provide a superior video quality and preserve the finest details in video content.
Allegro DVT’s D310 IP is part of the D3x0 highly customizable silicon IP family that builds on a scalable architecture allowing picture resolutions ranging from HD/4K up to 8K/16K while providing support for sample sizes from 8-bit to 12-bit and chroma subsampling from 4:0:0 up to 4:4:4.
Allegro DVT is able to address the growing demand of state-of-the-art video processing blocks in advanced System-on-Chips (SoCs) by providing highly configurable decoding IP cores supporting a variety of selectable codecs. In addition to AV1, the D3x0 family also supports JPEG, H.264, HEVC, VP9 and VVC video formats. Furthermore, its unique and scalable architecture approach offers the best trade-off between silicon size and power consumption keeping the operating frequency of the resulting solutions at a reasonable level to allow physical implementations in mainstream and cost-efficient process node technologies.
The D310 is immediately available with a comprehensive documentation and SW drivers for a smooth integration into video SoCs.
Nouar Hamze, CEO, commented “We are committed to supporting the AV1 ecosystem and accelerating the adoption of this promising video codec. Our D310 product is the very first AV1 Decoder IP to provide support for 12-bit pixel size and 4:4:4 chroma subsampling format. These high-end features will extend the breadth of target applications to includes advanced HDR, cloud-gaming, wireless display and automotive in which preserving video quality is of utmost importance. This IP represents the culmination of our engineering and marketing effort in bringing together the requirements of vastly different applications and generating optimal solutions in terms of power, performance, and area.”
About Allegro DVT
Allegro DVT, headquartered in Grenoble/France with offices in Belfast/Northern Ireland and Beijing/China, is a world leading provider of digital video technology solutions including compliance streams and video codec semiconductor IPs focused on the H.264/AVC, H.265/HEVC, AVS2, AVS3, VP9, AV1 and VVC standards.
For more information, visit our website or contact us
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005011/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 15:00:00 EET | Press release
Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end workflows spanning onboarding, KYC, AML, fraud, underwriting, payments, disputes, servicing, and collections. For
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom